Eyðniveiruprótínkljúfatálmar, lyfjablöndur sem slíkir tálmar eru í, lyfjafræðileg not þeirra, og efni til að smíða þá úr

Compounds of formula (I) where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. Theses compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts i...

Full description

Saved in:
Bibliographic Details
Main Authors STACIE S. CANON-KOCH, MARIA A. LINTON, STEPHEN E. WEBBER, GARY BOLTON, MARK BARVIAN, SCOTT C. VIRGIL, BENJAMIN J. BURKE, TANYA M. JEWELL, MICHAEL D. VARNEY, MICHAEL MELNICK, JOHN H. TATLOCK, STEPHEN T. WORLAND, THERESE N. ALEXANDER, JEFF MACHAK, SEAN T. MURPHY, FREDRICK E. BOYER, LENNERT J. MITCHELL, DONALD J. SKALITZKY, VARA PRASAD JOSYULA, TOD HOLLER, SIEGFRIED H. REICH
Format Patent
LanguageIcelandic
Published 21.11.2003
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Compounds of formula (I) where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. Theses compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
Bibliography:Application Number: IS20030007050